university website

S. Zweegman (Sonja), Stege, C.A.M., Haukas, E, Schjesvold, F.H., M.-D. Levin (Mark-David), A. Waage (Anders), R.B. Leys (Rieneke), Klein, SK, Szatkowski, D., Axelsson, P., et al. Do, T.H., Knut-Bojanowska, D., van der Spek, E., Svirskaite, A., Klostergaard, A., Salomo, M, Blimark, C., P.F. Ypma (Paula), U.H. Mellqvist (U. H.), Poddighe, P.J., M. Stevens-Kroef (Marian), N.W.C.J. van de Donk (Niels), P. Sonneveld (Pieter), Hansson, M, B. van der Holt (Bronno) and N. Abildgaard (Niels)

2020-12-01

Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

Publication

Publication

Haematologica , Volume 105 - Issue 12 p. 2879- 2882

Additional Metadata
Persistent URL doi.org/10.3324/haematol.2019.240374, hdl.handle.net/1765/133988
Journal Haematologica
Organisation Department of Hematology
Citation
Zweegman, S., Stege, C.A.M., Haukas, E, Schjesvold, F.H., Levin, M.-D., Waage, A., … Abildgaard, N. (2020). Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. Haematologica, 105(12), 2879–2882. doi:10.3324/haematol.2019.240374


User Publication Person Organisation Collection
Close